HealthCor Management

HeartFlow Inc., established in 2007 and headquartered in Redwood City, California, specializes in non-invasive coronary artery detection solutions. The company's flagship product, HeartFlow Analysis, employs artificial intelligence to generate a personalized 3D model of the heart using standard CT scan data. This enables clinicians worldwide to assess the impact of blockages on blood flow and determine optimal patient treatment, thereby reducing unnecessary invasive testing. HeartFlow operates additional offices in Portland (Oregon), Austin (Texas), London (UK), and Tokyo (Japan).

HeartFlow Inc., established in 2007 and headquartered in Redwood City, California, specializes in non-invasive coronary artery detection solutions. The company's flagship product, HeartFlow Analysis, employs artificial intelligence to generate a personalized 3D model of the heart using standard CT scan data. This enables clinicians worldwide to assess the impact of blockages on blood flow and determine optimal patient treatment, thereby reducing unnecessary invasive testing. HeartFlow operates additional offices in Portland (Oregon), Austin (Texas), London (UK), and Tokyo (Japan).

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapeutics. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond positively to specific treatments, thereby enhancing the effectiveness of its drug development efforts. Acrivon's pipeline features its lead program, ACR-368 (prexasertib), which is currently in Phase 2 trials, alongside several preclinical programs targeting key components of DNA damage response and cell cycle regulation, including WEE1 and PKMYT1. By concentrating on complex oncology drug targets that are often not addressed by traditional therapies, Acrivon aims to expedite the advancement of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials.

Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Paige is a company founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializing in computational pathology products aimed at enhancing diagnostic precision and treatment decision-making for cancer patients. The company has developed a platform that employs advanced deep learning algorithms, including convolutional and recurrent neural networks, to enable rapid diagnostic stratification and cancer detection, particularly for breast, prostate, and other major cancer types. This innovative technology is designed to transform the workflow of pathologists, providing them with insights that lead to more accurate diagnoses while minimizing the burden on IT systems and ensuring patient safety and data privacy. Paige is recognized as the first organization to receive FDA breakthrough designation for its computational pathology products.

Paige is a company founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializing in computational pathology products aimed at enhancing diagnostic precision and treatment decision-making for cancer patients. The company has developed a platform that employs advanced deep learning algorithms, including convolutional and recurrent neural networks, to enable rapid diagnostic stratification and cancer detection, particularly for breast, prostate, and other major cancer types. This innovative technology is designed to transform the workflow of pathologists, providing them with insights that lead to more accurate diagnoses while minimizing the burden on IT systems and ensuring patient safety and data privacy. Paige is recognized as the first organization to receive FDA breakthrough designation for its computational pathology products.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

PreemaTEX is the developer of an innovative, high value diagnostic tests focused on assessing a woman’s risk for preterm delivery early in pregnancy.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

HLS Therapeutics Inc is a specialty pharmaceutical company that focuses on the acquisition and commercialization of branded pharmaceutical products primarily in North America. The company is committed to managing the life cycles of these products after their exclusivity, ensuring that essential treatments remain accessible to patients and caregivers. HLS Therapeutics offers a range of products, including Clozaril and Vascepa, and generates revenue mainly through product sales, supplemented by royalties. Operating in Canada, the United States, and other international markets, HLS Therapeutics plays a crucial role in maintaining the availability of trusted medications.

Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.

Kellbenx Inc. is a biotechnology company established in 2010 and headquartered in Great River, New York. The company specializes in the development of non-invasive prenatal diagnostics aimed at identifying specific genetic and heritable disorders. By utilizing intact DNA, Kellbenx's diagnostic methods enable the detection of aneuploidies and a variety of genetic abnormalities, significantly enhancing women's healthcare. The company is committed to improving prenatal testing processes and outcomes through innovative technology in the field of genetics.

CareView Communications is a healthcare technology company that specializes in developing a proprietary network system designed to enhance patient safety and streamline hospital operations. Utilizing existing coaxial cable infrastructure, CareView offers a suite of software applications that include real-time patient monitoring to prevent falls, a bed management program for efficient patient placement, and a mobile application for nursing staff to manage patient care effectively. The company's solutions also feature communication tools such as VoIP, text, and email capabilities to facilitate efficient staff interactions. Additionally, CareView provides a guest services package that includes entertainment options to improve patient satisfaction, along with a patient education portal that offers easy access to educational resources for patients and their families. Overall, CareView Communications aims to improve healthcare delivery, enhance patient experiences, and boost hospital performance metrics.

Sadra Medical is dedicated to developing innovative therapies for treating aortic valve disease, focusing on minimally invasive alternatives to traditional surgical valve replacement. The company aims to improve patient care and expand treatment options for a broader range of patients by reducing the risks and morbidity associated with open-heart surgery. Sadra Medical's key product is the Lotus valve, a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure, along with the Lotus delivery catheter designed for precise placement of the valve. As a subsidiary of Boston Scientific, Sadra Medical addresses a significant unmet clinical need, as only a small percentage of the estimated 3 million people in the U.S. with aortic valve stenosis receive treatment through current standard procedures.

Access Closure, Inc. is a medical device company based in Mountain View, California, founded in 2002. The company specializes in developing access site management products focused on vascular closure during interventional and diagnostic procedures. Its primary offering is the Mynx delivery system, a vascular closure device designed to seal arteriotomies using a unique water-soluble and extravascular sealant. This sealant expands within the tissue tract by absorbing blood and subcutaneous fluids, effectively addressing the complexities associated with vascular closure. Access Closure aims to enhance patient outcomes and procedural efficiency in the field of vascular access.

ApaTech Ltd. is an ortho-biologics company specializing in the production of synthetic bone repair materials. Founded in 2001 and headquartered in Elstree, United Kingdom, the company offers a range of products designed to enhance bone formation and facilitate surgical procedures. Its flagship product, Actifuse, is a synthetic bone graft that promotes the formation of new bone in graft and host structures, making it suitable for small void filling and spinal fusion applications. Additionally, ApaTech provides ApaPore, a porous hydroxyapatite grafting material used for cemented revision of failed total joint arthroplasties, spinal fusions, fracture fixations, and treatment of bone defects. The Actifuse MIS Bone Graft Delivery System allows for controlled delivery and precise placement of the graft during both open and minimally invasive surgeries. ApaTech distributes its products across various countries, including those in Europe, the Middle East, and Australia, and maintains operations in London, Foxborough, Massachusetts, and Berlin, Germany.

Paradigm Spine, LLC is a privately-held medical device company specializing in the design and development of innovative solutions for spinal diseases. Headquartered in New York, the company focuses on non-fusion spinal implants and motion-preserving products aimed at treating various spinal disorders. Its notable offerings include the Coflex interspinous implant, which is used for managing facet arthrosis and decompressive procedures, and a minimally invasive pedicle-screw based system known as the DSS system. These products are designed to stabilize the spine while preserving natural anatomical function, catering to the needs of spine specialists globally. Established in 2002 and originally named Spine Motion, LLC, the company rebranded to Paradigm Spine in 2005.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.

HeartFlow Inc., established in 2007 and headquartered in Redwood City, California, specializes in non-invasive coronary artery detection solutions. The company's flagship product, HeartFlow Analysis, employs artificial intelligence to generate a personalized 3D model of the heart using standard CT scan data. This enables clinicians worldwide to assess the impact of blockages on blood flow and determine optimal patient treatment, thereby reducing unnecessary invasive testing. HeartFlow operates additional offices in Portland (Oregon), Austin (Texas), London (UK), and Tokyo (Japan).

Paradigm Spine, LLC is a privately-held medical device company specializing in the design and development of innovative solutions for spinal diseases. Headquartered in New York, the company focuses on non-fusion spinal implants and motion-preserving products aimed at treating various spinal disorders. Its notable offerings include the Coflex interspinous implant, which is used for managing facet arthrosis and decompressive procedures, and a minimally invasive pedicle-screw based system known as the DSS system. These products are designed to stabilize the spine while preserving natural anatomical function, catering to the needs of spine specialists globally. Established in 2002 and originally named Spine Motion, LLC, the company rebranded to Paradigm Spine in 2005.